Drugs and Companies using PIRFENIDONE ingredient

Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis; Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis; Dose escalation over 14 days for treatment of a fibrosis condition; Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-1600 mg/day, following by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-2400mg/day dose, followed by administering 2403mg/day in treatment of ipf; dosing 2403 mg/day pirfenidone following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-1600 mg/day dose, followed by administering at least 1600 mg/day dose in treatment of ipf; dosing of at least 1600 mg/day following grade 2 liver abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosing of at least 1600 mg/day following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose in treatment of ipf; Dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone; Discontinuing administration of fluvoxamine to avoid drug interactions with pirfenidone and then administering pirfenidone; administering pirfenidone while avoiding co-administration of fluvoxamine to avoid drug interactions with pirfenidone; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing a strong cyp1a2 inducer; Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder; administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder

Dosage: CAPSULE;ORAL